A 44-year-old patient comes in for a weight loss consultation. She has been on semaglutide for nine months. She lost twelve pounds in the first three months and has not lost a pound since. Her appetite is genuinely suppressed — she eats half of what she used to, sometimes less. But her abdomen is distended every afternoon, she belches constantly after meals, her stool quality is unpredictable, and her clothes do not fit any better in the waistband than they did six months ago even though the scale has moved slightly. Her last GI workup was a colonoscopy in 2019 that was normal. Nobody has ever asked her about bloating.
What I see when I evaluate her is not a GLP-1 failure. It is small intestinal bacterial overgrowth running underneath the GLP-1, generating fermentation that the medication's slowed gastric emptying is actually making worse. SIBO is one of the most common reasons mid-life patients plateau on GLP-1 therapy, and it is one of the least diagnosed contributors to weight loss resistance.
What SIBO actually is and how it gets missed
The small intestine — the duodenum, jejunum, and ileum — is supposed to be a relatively low-bacteria environment. That is not because bacteria are bad. It is because the small intestine is where you absorb nutrients from food, and its job depends on having a controlled microbial population. The colon is where the heavy bacterial fermentation is supposed to happen. The migrating motor complex — the cleansing wave that moves through the small intestine between meals about every 90 to 120 minutes — is the body's primary mechanism for keeping the small intestine relatively clean. Stomach acid, bile, pancreatic enzymes, and the ileocecal valve all contribute additional defense.
Small intestinal bacterial overgrowth is the condition where bacteria — usually species that belong further downstream in the colon — colonize the small intestine in numbers that disrupt normal digestion. When carbohydrate hits a small intestine that is overgrown, it ferments before it can be absorbed. Fermentation produces hydrogen gas, methane, or hydrogen sulfide depending on the dominant organisms. The gas distends the bowel. The fermentation byproducts irritate the intestinal lining and can drive low-grade inflammation, intestinal permeability, and downstream systemic effects.
The reason SIBO gets missed: the symptoms overlap with everything. Bloating, gas, fullness, alternating constipation and diarrhea, abdominal discomfort, post-meal fatigue, brain fog, food sensitivities that did not used to be problems. Patients are routinely told they have IBS — which is a description, not a diagnosis — and sent home with a fiber recommendation that often makes SIBO worse.
Why SIBO directly resists weight loss
There are three mechanisms I see consistently in SIBO patients that work against weight loss, and they stack on each other.
First, SIBO disrupts the production and signaling of the gut-brain hormones that regulate appetite, satiety, and metabolic rate. The microbiome of the small intestine is in direct contact with enteroendocrine cells that produce GLP-1, PYY, ghrelin, CCK, and other regulators. When the microbial population is wrong, the signaling is wrong. Patients describe feeling full immediately at the start of a meal but never satisfied after — a classic SIBO appetite pattern that runs in the opposite direction of normal satiety physiology.
Second, the chronic low-grade inflammation generated by SIBO fermentation drives systemic insulin resistance through inflammatory cytokine signaling — TNF-alpha, IL-6, lipopolysaccharide endotoxemia from increased intestinal permeability. Insulin resistance is one of the most direct biological causes of weight loss resistance, and SIBO is a steady upstream contributor that no amount of dietary change will fix while the overgrowth is active.
Third, SIBO alters energy harvest from food. Certain bacterial overgrowth patterns — particularly methane-dominant SIBO from organisms like Methanobrevibacter smithii — are independently associated with higher caloric extraction from the same intake, slowed transit time, and a constipation-predominant pattern that patients describe as "feeling like everything just sits there." The methanogen population literally extracts more calories per gram of food than a normal microbiome does, and the patient eats the same amount and gains weight from it.
The overall picture: SIBO produces a metabolic environment where appetite signaling is broken, insulin sensitivity is degraded, and caloric efficiency is increased. Weight loss in that environment is not impossible, but it is uphill against the wind.
Why GLP-1 sometimes makes SIBO worse before it gets better
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
This is the conversation I have to have carefully because patients hear it as criticism of GLP-1 therapy. It is not. GLP-1 medications work. But the same mechanism that makes them effective for appetite — slowed gastric emptying and reduced GI motility — can worsen the migrating motor complex, which is the body's primary anti-SIBO defense. In a patient with subclinical or undiagnosed SIBO, starting a GLP-1 can produce dramatic worsening of bloating, distention, reflux, and constipation, and can stall weight loss by reinforcing the bacterial overgrowth.
The patients who struggle most on GLP-1 therapy — the ones with disproportionate GI side effects, the ones who plateau early, the ones who cannot tolerate dose escalation — overlap heavily with the patients who have unrecognized SIBO. This is not a contraindication to GLP-1. It is a reason to evaluate the gut before assuming the medication is the problem.
How I evaluate for SIBO in a weight loss workup
When I suspect SIBO in a weight loss patient, I order a hydrogen and methane breath test — typically a glucose or lactulose substrate test, depending on the clinical picture. The test measures gas production over a three-hour window after the patient drinks the substrate. Elevated hydrogen suggests hydrogen-dominant SIBO. Elevated methane above 10 ppm at any point suggests intestinal methanogen overgrowth, which has a different treatment than hydrogen SIBO and is the form most associated with constipation and weight loss resistance.
Alongside the breath test, I look at the patient's history for the conditions that predispose to SIBO. Prior abdominal surgery, including C-section and gallbladder removal. Long-term proton pump inhibitor use. Opioid history. Hypothyroidism, which slows the migrating motor complex. Diabetes with autonomic neuropathy. A history of food poisoning that produced lasting symptom changes — post-infectious IBS is a recognized SIBO precursor. Chronic stress, which directly suppresses MMC activity. Prior frequent antibiotic exposure, which destabilizes the microbiome.
I also look at the labs we are already running for the metabolic workup. A fasting insulin that is higher than the rest of the picture suggests gut-driven inflammation feeding insulin resistance. A low B12 or low iron despite normal intake can reflect malabsorption from small intestinal pathology. A low vitamin D in someone with adequate sun exposure can also point upstream to gut inflammation.
How I treat SIBO inside a weight loss program
Treating SIBO well takes layered intervention. The antimicrobial phase is the obvious component — typically rifaximin, sometimes combined with neomycin or with a botanical antimicrobial protocol depending on the test result and the patient's preferences. Rifaximin is a non-absorbed antibiotic that works locally in the small intestine and has been studied specifically for SIBO and IBS-related conditions. For methane-positive cases, the protocol is different and usually requires combination therapy because methanogens are archaea, not bacteria, and respond differently to standard antibiotics.
The harder part is what comes after the antimicrobial phase: restoring motility so the SIBO does not relapse. The migrating motor complex needs to function for the small intestine to clear itself between meals. Prokinetic agents — sometimes prescription, sometimes natural compounds like ginger extract — are used in the post-treatment phase. Spacing meals four to five hours apart so the MMC has time to run is one of the most underappreciated parts of SIBO recovery. Stress management and sleep quality matter directly here because both affect autonomic regulation of gut motility.
Dietary structure during and after treatment is individualized. Some patients respond well to a temporary low-fermentable carbohydrate approach like low-FODMAP. Others tolerate broader intake from the start. Long-term restrictive diets are not the goal — they are sometimes a transitional tool. This is one of the places where nutritional counseling inside the weight loss program adds the most value, because the patient needs structured guidance through what is genuinely a complicated phase.
What I want you to do if this sounds like you
If your weight loss has been resistant — particularly if you are on GLP-1 therapy and have plateaued, or if you have chronic bloating that nobody has worked up properly — the next step is a comprehensive evaluation that actually includes the gut, not just the metabolic and hormonal panels. Bring a symptom log for the past two weeks if you can: bloating timing, bowel pattern, food triggers, post-meal energy, distention pattern. Bring any prior breath tests, GI workups, or antibiotic history. Bring your current medication and supplement list with exact doses.
Schedule the consultation at the Columbus clinic or the Warner Robins clinic. We will run the metabolic and hormonal workup, add the SIBO breath testing if the picture suggests it, and build the medical weight loss program around what is actually driving your resistance — not around the average patient's protocol. The patients I see plateau on GLP-1 and unlock progress after a SIBO workup are common enough that I now screen for it routinely. If your gut has been part of the picture all along, that is fixable, and the weight loss that follows the gut work is usually faster and more durable than any layered intervention before it.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.